Tailoring Treatment in Diabetes: The Patient as the Blueprint-GLP-1 RAs vs SGLT2 Inhibitors in Cardiovascular Outcomes
Witnessing the paradigm shift to NCDs calls for ever-evolving changes in how we treat patients with DM type 2,…
Browsing Category
1 article
